Actinium Pharmaceuticals, Inc.

AMEX:ATNM

4.27 (USD) • At close November 27, 2023
Bedrijfsnaam Actinium Pharmaceuticals, Inc.
Symbool ATNM
Munteenheid USD
Prijs 4.49
Beurswaarde 121,219,224
Dividendpercentage 0%
52-weken bereik 4.3 - 14.7
Industrie Biotechnology
Sector Healthcare
CEO Mr. Sandesh C. Seth M.B.A., M.S., MBA
Website https://www.actiniumpharma.com

An error occurred while fetching data.

Over Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or

Vergelijkbare Aandelen

Retractable Technologies, Inc. logo

Retractable Technologies, Inc.

RVP

1.08 USD

CEL-SCI Corporation logo

CEL-SCI Corporation

CVM

2.18 USD

Stereotaxis, Inc. logo

Stereotaxis, Inc.

STXS

1.56 USD

VolitionRx Limited logo

VolitionRx Limited

VNRX

0.748 USD

Matinas BioPharma Holdings, Inc. logo

Matinas BioPharma Holdings, Inc.

MTNB

0.235 USD

Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc.

ARMP

2.22 USD

Cybin Inc. logo

Cybin Inc.

CYBN

0.45 USD

Electromed, Inc. logo

Electromed, Inc.

ELMD

10.5 USD

Asensus Surgical, Inc. logo

Asensus Surgical, Inc.

ASXC

0.236 USD

Palatin Technologies, Inc. logo

Palatin Technologies, Inc.

PTN

1.96 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)